Antipsychotic Drugs Market - Trends, Size & Outlook (2024-2032)

Antipsychotic Drugs Market Synopsis

Antipsychotic Drugs Market Size Was Valued at USD 17.48 Billion in 2023, and is Projected to Reach USD 33.91 Billion by 2032, Growing at a CAGR of 7.63% From 2024-2032.

The antipsychotic drug industry means the market including products as pharmaceutical drugs designed mostly for the treatment of disorders of the schizophrenic, bipolar, major depressive, psychotic and similar natures. Al these antipsychotic drugs works by affecting neurotransmitters in the brain more specifically dopamine and serotonin and can be classified as first generation antipsychotics and second generation antipsychotics.

The Antipsychotic drug market has grown rapidly over the last few years due to rising incidences of mental disorders, the rise of the global population, and added awareness of mental ailments. This category consists of medications that are intended to alleviate symptoms of certain mental disorders such as schizophrenia, bipolar disease, and depression improving the drug forms and treatment courses gradually. These drugs are categorized into two main groups: as first generation (traditional) antipsychatics and second generation antipsychatics. It added that atypical antipsychotics are more effective with lesser side effects, hence a large contribution to market growth.

Strengthening of the sentiment that better mental health care is needed and the evolution in the technique of diagnosis are the key factors which have caused an increase in the utilization of antipsychotics. Additionally, the increasing importance attributed to mental health as an important component of general health is causing an expansion in funding and development of new psychotropic medications. There is also research being conducted to come up with new products and also improving on existing ones so as to increaseImproved patient care as pharmaceutical firms come up with long acting injectables in a bid to lower relapse among patients such as those who have schizophrenia. Nevertheless, the market has emerged with some disturbing events like side effects related to antipsychotics, issues of drug abuse and addition.

Antipsychotic Drugs Market Trend Analysis:

 The Rise of Long-Acting Injectables (LAIs)

• Among all the trends currently observable in the market of antipsychotic drugs, the tendency toward using long-acting injectable antipsychotics (LAIs) has been identified as the most striking one. LAIs have the advantage of being more constant in results compared to orally administered drugs that are hard for schizophrenic or any other psychoses patients to maintain. These are usually given after weeks or months, thus they minimize daily intake of medicines and enhance general drug compliance. LAI’s rise is being driven by the increasing concern for patient compliance to medication, since non-adherence results to relapses and re-hospitalization, which are expensive. Furthermore, long-acting injectables are considered even safer and more effective for patients with chronically mentally ill patients who are non-adherent to oral medications. Another factor that is driving growth in LAIs is the massive emphasis that pharmaceutical firm are placing on the production of better LAIs to cater for the growing market interest.

 Personalized Medicine in Psychiatry

• One of the biggest opportunities within the antipsychotic drug market is that of targeting therapy according to the patient’s sub-genotypes, current lifestyle and symptoms, and the exact diagnosis. Increasingly, such endeavours are being attempted for psychiatric disorders because conventional standardized treatments rarely are able to produce the desired results. New discoveries in the pharmacogenomics, the interactions between genes and drugs, mean that treated conditions such as schizophrenia, bipolar disorder and depression have the potential to be treated according to the specific genetic constitution of the patient. Due to this approach, the frequency of side effects should be lower, patient compliance should be higher and overall prognosis should be considerably better. Those electronics manufacturing companies that enhance their ability to link genetic tests and treatment approaches into their drug discovery programs are expected to benefit from this increasingly large market.

Antipsychotic Drugs Market Segment Analysis:

Antipsychotic Drugs Market is segmented on the basis of Outlook, Type, Application, and Region.

By Type, Atypical Antipsychotics segment is expected to dominate the market during the forecast period

• The atypical antipsychotics segment is likely to have higher market share throughout the forecast year as they are safer and are more effective than the typical antipsychotics. These drugs are called atypical or the second generation antipsychotics and have some advantages over the first generation drugs for schizophrenia, bipolar affective disorder and major depressive disorder because they also act on dopamine and serotonin receptors. This dual action assists in managing symptoms while restricting extra pyramidal side effects including tardive dyskinesia typical of; the first generation antipsychotics. As such, they are being prescribed as the first line drugs, and we find them dominating the market.
• Furthermore, the rise in the prevalence rate of psychiatric diseases; especially among the ageing population, is also boosting the demand for the segment. The increase in reported mental health diseases, along with the focus on proper treatment plans, should drive atypical antipsychotics in the market. The dynamics of drug formulation and launching of new generations of atypical antipsychotic are expected to help the market. Because more patient and healthcare providers are interested in the long-term therapeutic outcomes and quality of life, the segment’s growth rate will remain high during the forecast period.

By Application, Schizophrenia segment expected to held the largest share

• The schizophrenia segment by disorder type is expected to dominate the market throughout the forecast period because of the higher incidence and medical intricacy of this illness. Schizophrenia is a long-term severe mental disorder that has a profound impact on millions of global citizens, who can experience symptoms, like hallucinations, paranoid delusions, and a decreased level of cognitive abilities that let them perform common everyday tasks. Thus, there is an increased need for suitable pharmacological interventions for the treatment of the condition. Any treatment for schizophrenia patient begins with antipsychotics, which are categorized as the first generation and second generation antipsychotics. Patient base is quite large and as the disease is chronic, the requirement of treatment for schizophrenia will always remain constant, making this segment a market leader.
• The increasing patient load, new developments in antipsychotic therapies is strengthening the schizophrenia application segment. Current research is directed toward development of higher potency antipsychotic agents possessing better tolerability and fewer side effects that may influence the patient’s compliance with the treatment. In recent advances, healthcare practitioners are now in a position to manage the schizophrenia treatment according to the patient’s need and as such produce the best results. These factors will further help in sustaining the growth in the schizophrenia segment and keep that particular segment ahead of the other varieties in the market span>

Antipsychotic Drugs Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America will continue to lead the global demand for antipsychotic drugs, due to the increasing demand of antipsychotic medications coupled with advanced infrastructures in terms of health care and increased importance given to the mental health globally. This market is lead by United States mainly due to high healthcare expenditure, increasing elderly population and higher incidence of psychiatric disorders like schizophrenia and depression. Market for North America is expected to contribute more than 40% of the global antipsychotic drug market in 2023. Regional governmental and insurance support for mental health programs, rise in accessibility of psychiatry treatments, and leading drug manufacturing firms focused on mental wellness drugs are receivables for the region. Furthermore, the region’s well-developed healthcare also enables quick confirmation and launch of new processes including long-acting injectable and newer generation antipsychotics.

Active Key Players in the Antipsychotic Drugs Market

•  AbbVie Inc. (USA)
• AstraZeneca (UK)
•  Bristol-Myers Squibb (USA)
•  Eli Lilly and Company (USA)
•  H. Lundbeck A/S (Denmark)
• Johnson & Johnson (USA)
•  Merck & Co., Inc. (USA)
•  Mylan N.V. (USA)
•  Novartis AG (Switzerland)
•  Otsuka Pharmaceutical Co., Ltd. (Japan)
•  Pfizer Inc. (USA)
•  Roche Holding AG (Switzerland)
•  Sanofi S.A. (France)
•  Sumitomo Dainippon Pharma Co., Ltd. (Japan)
•  Teva Pharmaceutical Industries Ltd. (Israel)
• Other Active Players

Key Industry Developments in the Global Antipsychotic Drugs Market

• In April 2023, Teva Pharmaceuticals and MedinCell announced the FDA approval of UZEDY™ (risperidone) extended-release injectable suspension for treating schizophrenia in adults. This long-acting formulation offers flexible 1- and 2-month dosing intervals. In a Phase 3 trial, UZEDY showed up to an 80% reduction in the risk of relapse compared to placebo. UZEDY is administered as a subcutaneous injection using a pre-filled syringe with a 21-gauge needle, achieving therapeutic levels within 6-24 hours.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Antipsychotic Drugs Market by Outlook
 4.1 Antipsychotic Drugs Market Snapshot and Growth Engine
 4.2 Antipsychotic Drugs Market Overview
 4.3 First Generation
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 First Generation: Geographic Segmentation Analysis
 4.4 Second Generation
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Second Generation: Geographic Segmentation Analysis

Chapter 5: Antipsychotic Drugs Market by Type
 5.1 Antipsychotic Drugs Market Snapshot and Growth Engine
 5.2 Antipsychotic Drugs Market Overview
 5.3 Atypical Antipsychotics
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Atypical Antipsychotics: Geographic Segmentation Analysis
 5.4 Miscellaneous Antipsychotics Agents
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Miscellaneous Antipsychotics Agents: Geographic Segmentation Analysis

Chapter 6: Antipsychotic Drugs Market by Application
 6.1 Antipsychotic Drugs Market Snapshot and Growth Engine
 6.2 Antipsychotic Drugs Market Overview
 6.3 Schizophrenia
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Schizophrenia: Geographic Segmentation Analysis
 6.4 Anxiety
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Anxiety: Geographic Segmentation Analysis
 6.5 Bipolar Disorder
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Bipolar Disorder: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Antipsychotic Drugs Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 ABBVIE INC. (USA)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 ASTRAZENECA (UK)
 7.4 BRISTOL-MYERS SQUIBB (USA)
 7.5 ELI LILLY AND COMPANY (USA)
 7.6 H. LUNDBECK A/S (DENMARK)
 7.7 JOHNSON & JOHNSON (USA)
 7.8 MERCK & CO. INC. (USA)
 7.9 MYLAN N.V. (USA)
 7.10 NOVARTIS AG (SWITZERLAND)
 7.11 OTSUKA PHARMACEUTICAL CO. LTD. (JAPAN)
 7.12 PFIZER INC. (USA)
 7.13 ROCHE HOLDING AG (SWITZERLAND)
 7.14 SANOFI S.A. (FRANCE)
 7.15 SUMITOMO DAINIPPON PHARMA CO. LTD. (JAPAN)
 7.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
 7.17 OTHER ACTIVE PLAYERS

Chapter 8: Global Antipsychotic Drugs Market By Region
 8.1 Overview
 8.2. North America Antipsychotic Drugs Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Outlook
  8.2.4.1 First Generation
  8.2.4.2 Second Generation
  8.2.5 Historic and Forecasted Market Size By Type
  8.2.5.1 Atypical Antipsychotics
  8.2.5.2 Miscellaneous Antipsychotics Agents
  8.2.6 Historic and Forecasted Market Size By Application
  8.2.6.1 Schizophrenia
  8.2.6.2 Anxiety
  8.2.6.3 Bipolar Disorder
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Antipsychotic Drugs Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Outlook
  8.3.4.1 First Generation
  8.3.4.2 Second Generation
  8.3.5 Historic and Forecasted Market Size By Type
  8.3.5.1 Atypical Antipsychotics
  8.3.5.2 Miscellaneous Antipsychotics Agents
  8.3.6 Historic and Forecasted Market Size By Application
  8.3.6.1 Schizophrenia
  8.3.6.2 Anxiety
  8.3.6.3 Bipolar Disorder
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Bulgaria
  8.3.7.2 The Czech Republic
  8.3.7.3 Hungary
  8.3.7.4 Poland
  8.3.7.5 Romania
  8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe Antipsychotic Drugs Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Outlook
  8.4.4.1 First Generation
  8.4.4.2 Second Generation
  8.4.5 Historic and Forecasted Market Size By Type
  8.4.5.1 Atypical Antipsychotics
  8.4.5.2 Miscellaneous Antipsychotics Agents
  8.4.6 Historic and Forecasted Market Size By Application
  8.4.6.1 Schizophrenia
  8.4.6.2 Anxiety
  8.4.6.3 Bipolar Disorder
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 Netherlands
  8.4.7.5 Italy
  8.4.7.6 Russia
  8.4.7.7 Spain
  8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific Antipsychotic Drugs Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Outlook
  8.5.4.1 First Generation
  8.5.4.2 Second Generation
  8.5.5 Historic and Forecasted Market Size By Type
  8.5.5.1 Atypical Antipsychotics
  8.5.5.2 Miscellaneous Antipsychotics Agents
  8.5.6 Historic and Forecasted Market Size By Application
  8.5.6.1 Schizophrenia
  8.5.6.2 Anxiety
  8.5.6.3 Bipolar Disorder
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Antipsychotic Drugs Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Outlook
  8.6.4.1 First Generation
  8.6.4.2 Second Generation
  8.6.5 Historic and Forecasted Market Size By Type
  8.6.5.1 Atypical Antipsychotics
  8.6.5.2 Miscellaneous Antipsychotics Agents
  8.6.6 Historic and Forecasted Market Size By Application
  8.6.6.1 Schizophrenia
  8.6.6.2 Anxiety
  8.6.6.3 Bipolar Disorder
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkey
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Antipsychotic Drugs Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Outlook
  8.7.4.1 First Generation
  8.7.4.2 Second Generation
  8.7.5 Historic and Forecasted Market Size By Type
  8.7.5.1 Atypical Antipsychotics
  8.7.5.2 Miscellaneous Antipsychotics Agents
  8.7.6 Historic and Forecasted Market Size By Application
  8.7.6.1 Schizophrenia
  8.7.6.2 Anxiety
  8.7.6.3 Bipolar Disorder
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research